keyword
https://read.qxmd.com/read/38025427/editorial-alternative-treatments-to-classical-antidepressants-in-treatment-resistant-depression
#21
EDITORIAL
Georgios Mikellides, Theodoros Koutsomitros, Olympia Evagorou, Nikolaos Gkouvas, Kuan-Pin Su, Panayiota Michael
No abstract text is available yet for this article.
2023: Frontiers in Psychiatry
https://read.qxmd.com/read/37983198/psychedelia-the-interplay-of-music-and-psychedelics
#22
REVIEW
Katarina Jerotic, Peter Vuust, Morten L Kringelbach
Music and psychedelics have been intertwined throughout the existence of Homo sapiens, from the early shamanic rituals of the Americas and Africa to the modern use of psychedelic-assisted therapy for a variety of mental health conditions. Across such settings, music has been highly prized for its ability to guide the psychedelic experience. Here, we examine the interplay between music and psychedelics, starting by describing their association with the brain's functional hierarchy that is relied upon for music perception and its psychedelic-induced manipulation, as well as an exploration of the limited research on their mechanistic neural overlap...
January 2024: Annals of the New York Academy of Sciences
https://read.qxmd.com/read/37982394/drug-drug-interactions-involving-classic-psychedelics-a-systematic-review
#23
REVIEW
Andreas Halman, Geraldine Kong, Jerome Sarris, Daniel Perkins
Classic psychedelics, including lysergic acid diethylamide (LSD), psilocybin, mescaline, N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), are potent psychoactive substances that have been studied for their physiological and psychological effects. However, our understanding of the potential interactions and outcomes when using these substances in combination with other drugs is limited. This systematic review aims to provide a comprehensive overview of the current research on drug-drug interactions between classic psychedelics and other drugs in humans...
January 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/37979818/emotion-regulation-effects-of-ayahuasca-in-experienced-subjects-during-implicit-aversive-stimulation-an-fmri-study
#24
JOURNAL ARTICLE
Tiago Arruda Sanchez, Lucas Rego Ramos, Felipe Araujo, Eduardo Ekman Schenberg, Mauricio Yonamine, Isabela Lobo, Draulio Barros de Araujo, Luis Eduardo Luna
ETHNOPHARMACOLOGICAL RELEVANCE: Ayahuasca is a beverage used in Amazonian traditional medicine and it has been part of the human experience for millennia as well as other different psychoactive plants. Although Ayahuasca has been proposed as potentially therapeutic as an anxiolytic and antidepressant, whilst no studies have been carried out so far investigating their direct effect on brain emotional processing. AIM OF THE STUDY: This study aimed to measure the emotional acute effect of Ayahuasca on brain response to implicit aversive stimulation using a face recognition task in functional magnetic resonance imaging (fMRI)...
February 10, 2024: Journal of Ethnopharmacology
https://read.qxmd.com/read/37969069/assessment-of-the-acute-subjective-psychedelic-experience-a-review-of-patient-reported-outcome-measures-in-clinical-research-on-classical-psychedelics
#25
REVIEW
Oliver Rumle Hovmand, Emil Deleuran Poulsen, Sidse Arnfred
BACKGROUND: The classical psychedelics psilocybin, peyote, ayahuasca/ N, N-dimethyltryptamine, and lysergic acid diethylamide can temporarily produce altered states of consciousness, characterized by changes in sensory perception, thought, mood, and the sense of self-reality and meaning. It is important to have reliable instruments for quantifying these altered states in trials, due to a plausible link between the acute subjective experience and treatment outcome. METHODS: We conducted a review of outcome measures applied in research on classical psychedelics to assess one or more dimensions of the acute subjective psychedelic experience...
November 16, 2023: Journal of Psychopharmacology
https://read.qxmd.com/read/37968944/efficacy-and-safety-of-four-psychedelic-assisted-therapies-for-adults-with-symptoms-of-depression-anxiety-and-posttraumatic-stress-disorder-a-systematic-review-and-meta-analysis
#26
REVIEW
Anees Bahji, Isis Lunsky, Gilmar Gutierrez, Gustavo Vazquez
There has been a resurgence in psychedelic research for managing psychiatric conditions in recent years. This study aimed to present a comprehensive review of the current state of the field by applying a systematic search strategy for articles on the effectiveness and tolerability of four psychedelic-assisted therapies (psilocybin, lysergic acid diethylamide [LSD], 3,4-Methylenedioxymethamphetamine [MDMA], and ayahuasca) for adults with symptoms of depression, anxiety, and posttraumatic stress disorder (PTSD)...
November 15, 2023: Journal of Psychoactive Drugs
https://read.qxmd.com/read/37949934/a-quantitative-textual-analysis-of-the-subjective-effects-of-ayahuasca-in-na%C3%A3-ve-users-with-and-without-depression
#27
JOURNAL ARTICLE
Lucas Cruz, Bheatrix Bienemann, Fernanda Palhano-Fontes, Luís Fernando Tófoli, Dráulio B Araújo, Daniel C Mograbi
Ayahuasca is a brew with psychoactive properties that has been used as an entheogen for centuries, with more recent studies suggesting it is a promising treatment for some clinical disorders. Although there is an emerging scientific literature on its effects, to the best of our knowledge no study has explored the self-reported experiences of first-time ayahuasca users with quantitative textual analysis tools. Accordingly, the current study aimed to analyze the subjective experience of naive individuals with depression and healthy controls after consuming ayahuasca...
November 10, 2023: Scientific Reports
https://read.qxmd.com/read/37948338/ancient-medicine-for-a-modern-disease-traditional-amazonian-medicine-to-treat-substance-use-disorders
#28
REVIEW
Fernando Mendive, Cecile Giovannetti, Sara García Arce
Background: There exists an underexploited opportunity to develop innovative therapeutic approaches to SUDs based upon the complementarity between modern and traditional health systems. Objectives: Illustrate the feasibility and potentiality of such an approach through the comprehensive description of Takiwasi Center's treatment model and program, where health concepts and practices from traditional Amazonian medicine work synergistically with modern psychotherapy and medicine in an intercultural dialog to assist in the rehabilitation of people suffering from SUDs...
November 2, 2023: American Journal of Drug and Alcohol Abuse
https://read.qxmd.com/read/37947195/psychedelics-for-treatment-resistant-depression-are-they-game-changers
#29
REVIEW
Michail Kalfas, Rosie H Taylor, Dimosthenis Tsapekos, Allan H Young
INTRODUCTION: A new era of treatment for adults with treatment-resistant depression (TRD), which involves psychedelic substances, is dawning. Emerging evidence indicates that psychedelics can exert antidepressant effects through multiple neurobiological and psychological mechanisms. However, it remains to be seen if these new treatments will revolutionize the treatment of TRD. AREAS COVERED: The present review focuses on the efficacy of serotoninergic psychedelics psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), ayahuasca, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and mescaline (3,4,5-trimethoxyphenethylamine), as well as 3,4-methylenedioxymethamphetamine (MDMA), for TRD...
2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/37944438/present-and-future-of-metabolic-and-metabolomics-studies-focused-on-classical-psychedelics-in-humans
#30
REVIEW
Francisco Madrid-Gambin, David Fabregat-Safont, Alex Gomez-Gomez, Eulàlia Olesti, Natasha L Mason, Johannes G Ramaekers, Oscar J Pozo
Psychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attention to the possible use of classical psychedelics for the treatment of certain mental health disorders. However, further investigation to better understand their biological effects in humans, their mechanism of action, and their metabolism in humans is needed when considering the development of future novel therapeutic approaches. Both metabolic and metabolomics studies may help for these purposes...
December 31, 2023: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/37943076/ayahuasca-ceremony-leaders-perspectives-on-special-considerations-for-eating-disorders
#31
JOURNAL ARTICLE
Meris Williams, Annie Kingston Miller, Adele Lafrance
Eating disorders (EDs) are difficult conditions to resolve, necessitating novel treatments. Ayahuasca, a psychedelic plant medicine originating in Indigenous Amazonian communities, is being investigated. Aspects of ceremonial ayahuasca use (purging, dietary restrictions) appear similar to ED behaviors, raising questions about ayahuasca's suitability as an intervention for individuals with EDs. This study explored the perspectives of ayahuasca ceremony leaders on these and other considerations for ceremonial ayahuasca drinking among individuals with EDs...
2024: Eating Disorders
https://read.qxmd.com/read/37916667/-n-n-dimethyltryptamine-forms-oxygenated-metabolites-via-cyp2d6-an-in-vitro-investigation
#32
JOURNAL ARTICLE
Emma Eckernäs, Alicia Macan-Schönleben, Moa Andresen-Bergström, Sofia Birgersson, Kurt-Jürgen Hoffmann, Michael Ashton
N, N -dimethyltryptamine (DMT) is a psychedelic compound that has shown potential in the treatment of depression. Aside from the primary role of monoamine oxidase A (MAO-A) in DMT metabolism, the metabolic pathways are poorly understood. Increasing this understanding is an essential aspect of ensuring safe and efficacious use of DMT.This work aimed to investigate the cytochrome 450 (CYP) mediated metabolism of DMT by incubating DMT with recombinant human CYP enzymes and human liver microsomes (HLM) followed by analysis using high-resolution mass spectrometry for metabolite identification...
November 2, 2023: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://read.qxmd.com/read/37904854/corrigendum-ceremonial-ayahuasca-in-amazonian-retreats-mental-health-and-epigenetic-outcomes-from-a-six-month-naturalistic-study
#33
Simon G D Ruffell, Nige Netzband, WaiFung Tsang, Merlin Davies, Antonio Inserra, Matthew Butler, James J H Rucker, Luís Fernando Tófoli, Emma Louise Dempster, Allan H Young, Celia J A Morgan
[This corrects the article DOI: 10.3389/fpsyt.2021.687615.].
2023: Frontiers in Psychiatry
https://read.qxmd.com/read/37897244/psychological-and-physiological-effects-of-extended-dmt
#34
RANDOMIZED CONTROLLED TRIAL
Lisa X Luan, Emma Eckernäs, Michael Ashton, Fernando E Rosas, Malin V Uthaug, Alexander Bartha, Samantha Jagger, Kiara Gascon-Perai, Lauren Gomes, David J Nutt, David Erritzøe, Robin L Carhart-Harris, Christopher Timmermann
N,N-Dimethyltryptamine (DMT) is a serotonergic psychedelic that induces a rapid and transient altered state of consciousness when inhaled or injected via bolus administration. Its marked and novel subjective effects make DMT a powerful tool for the neuroscientific study of consciousness and preliminary results show its potential role in treating mental health conditions. In a within-subjects, placebo-controlled study, we investigated a novel method of DMT administration involving a bolus injection paired with a constant-rate infusion, with the goal of extending the DMT experience...
January 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/37874530/cardiovascular-safety-of-psychedelic-medicine-current-status-and-future-directions
#35
REVIEW
Agnieszka Wsół
Psychedelics are powerful psychoactive substances that alter perception and mood processes. Their effectiveness in the treatment of psychiatric diseases was known before their prohibition. An increasing number of recent studies, due to the indisputable resurgence of serotonergic hallucinogens, have shown their efficacy in alleviating depression, anxiety, substance abuse therapies, and existential distress treatment in patients facing life-threatening illness. Psychedelics are generally considered to be physiologically safe with low toxicity and low addictive potential...
December 2023: Pharmacological Reports: PR
https://read.qxmd.com/read/37869749/bedside-to-bench-the-outlook-for-psychedelic-research
#36
REVIEW
Victor P Acero, Emily S Cribas, Kevin D Browne, Olivia Rivellini, Justin C Burrell, John C O'Donnell, Suradip Das, D Kacy Cullen
There has recently been a resurgence of interest in psychedelic compounds based on studies demonstrating their potential therapeutic applications in treating post-traumatic stress disorder, substance abuse disorders, and treatment-resistant depression. Despite promising efficacy observed in some clinical trials, the full range of biological effects and mechanism(s) of action of these compounds have yet to be fully established. Indeed, most studies to date have focused on assessing the psychological mechanisms of psychedelics, often neglecting the non-psychological modes of action...
2023: Frontiers in Pharmacology
https://read.qxmd.com/read/37869513/cortical-structural-differences-following-repeated-ayahuasca-use-hold-molecular-signatures
#37
JOURNAL ARTICLE
Pablo Mallaroni, Natasha L Mason, Lilian Kloft, Johannes T Reckweg, Kim van Oorsouw, Johannes G Ramaekers
INTRODUCTION: Serotonergic psychedelics such as ayahuasca are reported to promote both structural and functional neural plasticity via partial 5-HT2A agonism. However, little is known about how these molecular mechanisms may extend to repeated psychedelic administration in humans, let alone neuroanatomy. While early evidence suggests localised changes to cortical thickness in long-term ayahuasca users, it is unknown how such findings may be reflected by large-scale anatomical brain networks comprising cytoarchitecturally complex regions...
2023: Frontiers in Neuroscience
https://read.qxmd.com/read/37841918/a-pilot-study-of-cerebral-metabolism-and-serotonin-5-ht-2a-receptor-occupancy-in-rats-treated-with-the-psychedelic-tryptamine-dmt-in-conjunction-with-the-mao-inhibitor-harmine
#38
JOURNAL ARTICLE
Klemens Egger, Frederik Gudmundsen, Naja Støckel Jessen, Christina Baun, Sandra N Poetzsch, Vladimir Shalgunov, Matthias M Herth, Boris B Quednow, Chantal Martin-Soelch, Dario Dornbierer, Milan Scheidegger, Paul Cumming, Mikael Palner
Rationale: The psychedelic effects of the traditional Amazonian botanical decoction known as ayahuasca are often attributed to agonism at brain serotonin 5-HT2A receptors by N,N -dimethyltryptamine (DMT). To reduce first pass metabolism of oral DMT, ayahuasca preparations additionally contain reversible monoamine oxidase A (MAO-A) inhibitors, namely β-carboline alkaloids such as harmine. However, there is lacking biochemical evidence to substantiate this pharmacokinetic potentiation of DMT in brain via systemic MAO-A inhibition...
2023: Frontiers in Pharmacology
https://read.qxmd.com/read/37750012/ayahuasca-personality-and-acute-psychological-effects-in-neo-shamanic-and-religious-settings-in-uruguay
#39
JOURNAL ARTICLE
Ismael Apud, Juan Scuro, Luisina Rodríguez, Gonzalo Hernandez, Ignacio Carrera, Frank Lozano, Juan Ignacio Retta
This study is an interdisciplinary research into Uruguayan ayahuasca users belonging to one neo-shamanic and one Santo Daime group. The study involved the chemical analysis of ayahuasca samples, an ethnographic description of the two traditions and rituals, and the application of psychometric scales to measure personality differences, and the acute psychological effects during an ayahuasca ritual. Personality measurements showed lower scores for Santo Daime in Neuroticism-Anxiety, Dependence, Low Self-Esteem, Anger and Restlessness...
September 25, 2023: Journal of Psychoactive Drugs
https://read.qxmd.com/read/37675972/therapeutic-effects-of-ceremonial-ayahuasca-use-for-methamphetamine-use-disorders-and-other-mental-health-challenges-case-studies-in-an-indigenous-community-in-sonora-mexico
#40
JOURNAL ARTICLE
Anja Loizaga-Velder, Cecile Giovannetti, Ricardo Campoy Gomez, Teresa Eduwiges Castillo Valenzuela, Gloria Rachel Ochoa Jaime, Gabrielle Agin-Liebes, Olivia Marcus, Brian Rush
This paper describes three case studies from an outpatient intercultural therapeutic program founded and run by Yaqui health professionals and traditional healers to serve members of the Yaqui tribe residing in Sonora, Mexico. This pilot therapeutic program has been designed specifically for Indigenous individuals, incorporating the ceremonial use of naturally derived psychedelics in addressing substance use disorders and other mental health issues. The program employs a community-based approach, integrating various traditional Indigenous healing practices like the sweatlodge ( temazcal ), medicinal plant preparations, and the ritualistic use of selected psychedelics from natural sources (such as ayahuasca, peyote, and secretions from Incilius alvarius )...
2023: Journal of Psychoactive Drugs
keyword
keyword
20868
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.